First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States

Importance: In the open-label phase III POSEIDON randomized clinical trial (RCT), a limited course of tremelimumab plus durvalumab and chemotherapy (T + D + CT) indicated in the first-line treatment of metastatic non-small cell lung cancer (mNSCLC), progression-free survival, and overall survival (O...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wenjie Liu (Autor), Gengwei Huo (Autor), Peng Chen (Autor)
Formato: Libro
Publicado: Frontiers Media S.A., 2023-07-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible